Search Results - "Burger, David M."

Drug–Drug Interaction Management with the Novel Anti-Cytomegalovirus Agents Letermovir and Maribavir: Guidance for Clinicians.

Authors: Burger, David M. Nijboer, Laura Ghobreyal, Mira et al.

Source: Clinical Pharmacokinetics. Nov2024, Vol. 63 Issue 11, p1529-1546. 18p.

Review article: clinical pharmacology of current and investigational hepatitis B virus therapies.

Authors: Smolders, Elise J. Burger, David M. Feld, Jordan J. et al.

Source: Alimentary Pharmacology & Therapeutics. Jan2020, Vol. 51 Issue 2, p231-243. 13p. 1 Diagram, 3 Charts.

What the Product Label Does Not Tell You About Drug–Drug Interaction Management: Time for a Re‐Appraisal.

Authors: Burger, David M. le Comte, Marianne Smolders, Elise J. et al.

Source: Journal of Clinical Pharmacology. Nov2023, Vol. 63 Issue 11, p1181-1185. 5p.

Pharmacokinetics and pharmacodynamics of azithromycin in severe malaria bacterial co-infection in African children (TABS-PKPD): a protocol for a Phase II randomised controlled trial.

Authors: Olupot-Olupot, Peter Okiror, William Mnjalla, Hellen et al.

Source: Wellcome Open Research. 2023, p1-24. 24p.

Subject Terms: *Malaria, *Bacterial communities, Pharmacokinetics, Pharmacodynamics, Azithromycin

A pharmacokinetic study to guide dosing of tenofovir disoproxil fumarate during different modalities of renal replacement therapy.

Authors: Dams, Karolien Burger, David M. Weyler, Jonas et al.

Source: Clinical Biochemistry. Sep2020, Vol. 83, p86-88. 3p.

Cobicistat: A case of mislabelled drug‐drug interaction risk?

Authors: Burger, David M. Calmy, Alexandra Marzolini, Catia

Source: British Journal of Clinical Pharmacology. May2020, Vol. 86 Issue 5, p834-836. 3p. 1 Chart.

Population Pharmacokinetics of Cobicistat and its Effect on the Pharmacokinetics of the Anticancer Drug Olaparib: Population Pharmacokinetics of Cobicistat and Its use as Pharmacokinetic Booster for Olaparib: J. K. Overbeek et al.

Authors: Overbeek, Joanneke K. van Erp, Nielka P. Burger, David M. et al.

Source: Clinical Pharmacokinetics. Mar2025, Vol. 64 Issue 3, p425-435. 11p.

The Pharmacology of Antiretroviral Nucleoside and Nucleotide Reverse Transcriptase Inhibitors.

Authors: Black, David J. Burger, David M. Flexner, Charles W. et al.

Source: JAIDS: Journal of Acquired Immune Deficiency Syndromes. 8/1/2005 Supplement, Vol. 39, pS1-S23. 23p. 3 Diagrams, 10 Charts, 5 Graphs.

This result is not displayed to guests.
Login for full access.

A Retrospective, Cohort-Based Survey of Patients Using Twice-Daily Indinavir + Ritonavir Combinations: Pharmacokinetics, Safety, and Efficacy.

Authors: Burger, David M. Hugen, Patricia W. H.

Source: JAIDS: Journal of Acquired Immune Deficiency Syndromes. 3/1/2001, Vol. 26 Issue 3, p218. 7p. 3 Charts, 2 Graphs.

Dose-Finding Study of a Once-Daily Indinavir/Ritonavir Regimen.

Authors: Hugen, Patricia W.H. Burger, David M.

Source: JAIDS: Journal of Acquired Immune Deficiency Syndromes. 11/1/2000, Vol. 25 Issue 3, p236. 10p. 3 Charts, 3 Graphs.

Pharmacokinetics of dolutegravir, tenofovir and lamivudine during venous–venous extracorporeal membrane oxygenation (VV‐ECMO): A case report.

Authors: Zwart, Tom C. Leegwater, Emiel Ottens, Thomas H. et al.

Source: British Journal of Clinical Pharmacology. May2026, Vol. 92 Issue 5, p1487-1492. 6p.

Managing drug–drug interactions in an HIV-infected patient receiving antiretrovirals, anti-HCV therapy and carbamazepine: A ‘tour de force’ for clinical pharmacologists.

Authors: Burger, David M. Arends, Joop E. Jacobs, Birgit S. et al.

Source: International Journal of Antimicrobial Agents. Jul2014, Vol. 44 Issue 1, p86-88. 3p.

The effect of the CYP2C19* 2 heterozygote genotype on the pharmacokinetics of nelfinavir.

Authors: Burger, David M. Schwietert, H. Reinier Colbers, E. P. H. (Angela) et al.

Source: British Journal of Clinical Pharmacology. Aug2006, Vol. 62 Issue 2, p250-252. 3p. 1 Graph.

Population Pharmacokinetics of Dolutegravir in African Children: Results From the CHAPAS-4 Trial.

Authors: Waalewijn, Hylke Wasmann, Roeland E Bamford, Alasdair et al.

Source: Journal of the Pediatric Infectious Diseases Society. Sep2024, Vol. 13 Issue 9, p496-500. 5p.

First-line antiretroviral therapy initiation for newly diagnosed people with HIV in the Netherlands: A retrospective analysis from 2016 to 2020.

Authors: Oosterhof, Piter Wit, Ferdinand W. N. M. van Luin, Matthijs et al.

Source: PLoS ONE. 7/26/2024, Vol. 19 Issue 7, p1-14. 14p.

Availability and stock‐outs of paediatric antiretroviral treatment formulations at health facilities in Kenya and Uganda.

Authors: Jacobs, Tom G. Okemo, Dorothy Ssebagereka, Anthony et al.

Source: HIV Medicine. Jul2024, Vol. 25 Issue 7, p805-816. 12p.

Mapping drug-drug interactions in pharmacokinetic boosting of olaparib.

Authors: Overbeek, Joanneke K. Naoom, Sarmad M. S. Nijboer, Laura et al.

Source: Cancer Chemotherapy & Pharmacology. 1/19/2026, Vol. 96 Issue 1, p1-5. 5p.

First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe Pneumonia.

Authors: Chabala, Chishala Jacobs, Tom G Moraleda, Cinta et al.

Source: Journal of the Pediatric Infectious Diseases Society. Nov2023, Vol. 12 Issue 11, p581-585. 5p.

Lamivudine and Emtricitabine Dosing Proposal for Children with HIV and Chronic Kidney Disease, Supported by Physiologically Based Pharmacokinetic Modelling.

Authors: Jacobs, Tom G. de Hoop-Sommen, Marika A. Nieuwenstein, Thomas et al.

Source: Pharmaceutics. May2023, Vol. 15 Issue 5, p1424. 16p.